Payment overview · 2025
General Payments
$1,123.43
55 reported records · 14 companies
Healthcare provider profile · identity verified
Leon A Yasay, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ORANGE PARK, FL · NPI 1295719250
Verified facts
What the public records show
CMS Open Payments records show Leon A Yasay, MD received $1,123.43 in general payments during 2025 across 55 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Rybelsus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $224.36 | 20.0% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $129.79 | 11.6% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $108.11 | 9.6% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $100.66 | 9.0% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $100.61 | 9.0% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $90.28 | 8.0% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $88.71 | 7.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $87.20 | 7.8% | 5 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $49.81 | 4.4% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $39.83 | 3.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.83 | 2.9% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $26.01 | 2.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.62 | 2.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $21.61 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,123.43 | 55 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $149.21 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $125.09 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $100.66 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $100.61 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $99.36 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $90.28 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $88.71 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $71.27 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $69.77 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $69.77 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $62.60 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $58.52 | 5 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $49.81 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $45.51 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $39.83 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.29 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $26.01 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.62 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 58 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 78 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
82 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 532 | 159 |
| Atorvastatin Calcium | Atorvastatin Calcium | 477 | 147 |
| Levothyroxine Sodium | Levothyroxine Sodium | 322 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 319 | 99 |
| Losartan Potassium | Losartan Potassium | 289 | 78 |
| Lisinopril | Lisinopril | 269 | 82 |
| Omeprazole | Omeprazole | 249 | 72 |
| Carvedilol | Carvedilol | 238 | 69 |
| Metformin Hcl | Metformin Hcl | 185 | 56 |
| Alprazolam | Alprazolam | 184 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 172 | 39 |
| Montelukast Sodium | Montelukast Sodium | 170 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 169 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 163 | 50 |
| Gabapentin | Gabapentin | 153 | 55 |
| Sertraline Hcl | Sertraline Hcl | 147 | 43 |
| Ezetimibe | Ezetimibe | 143 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 40 |
| Tramadol Hcl | Tramadol Hcl | 118 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 100 | 21 |
| Eliquis | Apixaban | 99 | 22 |
| Telmisartan | Telmisartan | 95 | 27 |
| Allopurinol | Allopurinol | 89 | 27 |
| Valsartan | Valsartan | 89 | 28 |
| Azithromycin | Azithromycin | 88 | 67 |
| Atenolol | Atenolol | 87 | 25 |
| Simvastatin | Simvastatin | 87 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 28 |
| Furosemide | Furosemide | 84 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 82 | 18 |
| Synthroid | Levothyroxine Sodium | 82 | 15 |
| Jardiance | Empagliflozin | 78 | 22 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 70 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 25 |
| Nifedipine Er | Nifedipine | 68 | 22 |
| Lorazepam | Lorazepam | 67 | 17 |
| Metformin Hcl Er | Metformin Hcl | 67 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 34 |
| Ozempic | Semaglutide | 61 | 17 |
| Glipizide | Glipizide | 59 | 18 |
| Mirtazapine | Mirtazapine | 59 | 19 |
| Farxiga | Dapagliflozin Propanediol | 58 | 13 |
| Rybelsus | Semaglutide | 55 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 53 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 53 | 25 |
| Meloxicam | Meloxicam | 53 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 14 |
| Prednisone | Prednisone | 52 | 30 |
| Sumatriptan Succinate | Sumatriptan Succinate | 51 | suppressed |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Januvia | Sitagliptin Phosphate | 49 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 16 |
| Bupropion Xl | Bupropion Hcl | 46 | 12 |
| Alendronate Sodium | Alendronate Sodium | 45 | 15 |
| Topiramate | Topiramate | 44 | 12 |
| Famotidine | Famotidine | 43 | 15 |
| Terazosin Hcl | Terazosin Hcl | 43 | suppressed |
| Irbesartan | Irbesartan | 41 | 12 |
| Trazodone Hcl | Trazodone Hcl | 41 | 15 |
| Clonazepam | Clonazepam | 40 | suppressed |
| Repaglinide | Repaglinide | 40 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | suppressed |
| Celecoxib | Celecoxib | 38 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 37 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | 11 |
| Diazepam | Diazepam | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 28 |
| Pregabalin | Pregabalin | 36 | suppressed |
| Potassium Chloride | Potassium Chloride | 35 | 15 |
| Ramipril | Ramipril | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Estradiol | Estradiol | 33 | 11 |
| Finasteride | Finasteride | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 16 |
| Sildenafil Citrate | Sildenafil Citrate | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 27 |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | 13 |
| Spironolactone | Spironolactone | 27 | suppressed |
| Cefdinir | Cefdinir | 26 | 22 |
| Methylprednisolone | Methylprednisolone | 26 | 21 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | 11 |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Baclofen | Baclofen | 23 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | 15 |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Zaleplon | Zaleplon | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | 11 |
| Meclizine Hcl | Meclizine Hcl | 20 | 12 |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Nateglinide | Nateglinide | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 13 |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Quviviq | Daridorexant Hcl | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,123.43 · 55 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, Korlym, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, Senza, TRELEGY ELLIPTA, TZIELD, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error